Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients
Open accessThe DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
Abstract
Background: Programmed death-ligand 1 (PD-L1) may be induced by oncogenic signals or can be upregulated via interferon gamma (IFN-γ). We have explored whether the expression of IFNG, the gene encoding IFN-γ, is associated with clinical response to the immune checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma patients. The role of inflammation-associated transcription factors STAT3, IKBKE, STAT1 and other associated genes has also been examined. Methods: Total RNA from 17 NSCLC and 21 melanoma patients was analyzed by quantitative reverse transcription PCR. STAT3 and Rantes, YAP1 and CXCL5, DNMT1, RIG1 and TET1, EOMES, IFNG, PD-L1 and CTLA4, IKBKE and NFATC1 mRNA were examined. PD-L1 protein expression in tumor and immune cells and stromal infiltration of CD8 + T-cells were also evaluated. Progression-free survival and overall survival were estimated. Results: A total of 17 NSCLC patients received nivolumab and 21 melanoma patients received pembrolizumab. Progression-free survival with nivolumab was significantly longer in NSCLC patients with high versus low IFNG expression (5.1 months versus 2 months, p = 0.0124). Progression-free survival with pembrolizumab was significantly longer in melanoma patients with high versus low IFNG expression (5.0 months versus 1.9 months, p = 0.0099). Significantly longer overall survival was observed for melanoma patients with high versus low IFNG expression (not reached versus 10.2 months p = 0.0183). There was a trend for longer overall survival for NSCLC patients with high versus low IFNG expression. Conclusions: IFN-γ is an important marker for prediction of response to immune checkpoint blockade. Further research is warranted in order to validate whether IFNG is more accurate than PD-L1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1. Immune suppressive and immune stimulating signaling pathways explored in our study. Signal transducer and activator of transcription 3 (STAT3) activates the DNA methyltransferase 1 (DNMT1), which silences the expression of interferon regulatory factors (IRFs), HLA molecules and subunits of the immunoproteasome complex (PSMB8 and PSMB9). The immunoproteasome facilitates antigen presentation for CD8+ T-cell responses. Ten eleven translocation 1 (TET1) enhances the activity of DNMT inhibitors. TET1 activity is upregulated by ascorbic acid. STAT3 can also indirectly inhibit the expression and activation of STAT1 and further reduce antigen presentation. Retinoic acid inducible gene-1 (RIG1) is one of the three RNA-sensing proteins [the other two are toll-like receptor-3 (TLR3) and melanoma differentiation associated gene-5 (MDA-5)] that induces interferon type I responses. Key transcription factors involved in RIG1 signaling include IRF3, IRF7 and NF-κB. Yes-Associated Protein 1 (YAP1) through a CXCL5–CXCR2 signaling axis drives myeloid-derived suppressor cell (MDSC) recruitment. STAT3 regulates the expression of Rantes (regulated upon activation, normal T-cell expressed and presumably secreted), also known as CCL5 and contributes to the recruitment of MDSCs. STAT3 increases the expression of genes encoding the calcium-binding proinflammatory proteins S100A and S100B. S100A and B activate cell surface receptors like toll-like receptor 4 (TLR4). A key downstream signal effect of TLR4 is mediated by activation of nuclear factor-kappa B (NF-κB), which produces large amounts of inflammatory cytokines like IL-6 and eventually STAT3 activation. Activated STAT3 has been demonstrated to bind to multiple sites in the arginase I promoter. High levels of arginase activity suppress CD8+ T-cell function and mediate MDSCs immune suppressive action. The T-box transcription factor eomesodermin (EOMES) maintains exhausted CD8+ T-cells. The noncanonical IκB kinase family member IKBKE (also called IKKε and IKKi), induced by tobacco components, regulates immune response by phosphorylating and activating STAT1. IKBKE can also negatively regulate T-cell immune responses through phosphorylating the nuclear factor of activated T-cells c1 (NFATc1) which complexes with STAT3 and cooperates in transcriptional regulation. DNMT1, DNA methyltransferase 1; EOMES, eomesodermin; HLA, human leukocyte antigen; IL, interleukin; IRF, interferon regulatory factors; LPS, lipopolysaccharide; MDA-5, melanoma differentiation associated gene-5; MDSC, myeloid-derived suppressor cells; NFATc1, nuclear factor of activated T-cells c1; NF-κB; nuclear factor-kappa B; PD-1, programmed death 1; PD-L1, programmed death-ligand 1; RIG1, retinoic acid inducible gene-1; STAT3, signal transducer and activator of transcription 3; TET1, ten eleven translocation 1; TLR3, toll-like receptor-3; TLR4, toll-like receptor 4; TME, tumor microenvironment; YAP1, Yes-Associated Protein 1.](https://figures.cochat.ai/paper-figures/8d0aab9561594691aab7d060ff6dae7a/interferon-gamma-an-important-marker-of-response-to-immune-checkpoint-blockade-figure-1.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In the clinic, a strong IFN-γ signature has been identified as a useful predictor and indicator of response in anti-PD-1-treated patients across various cancer indications (75,92,93).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [92]
In the citing paper
“In regards to tumor control, IFN-γ has pleiotropic effects, and is critical for anti-PD-1 efficacy by promoting immune surveillance37.”
From Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation (2019) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Guo, J., Kim, D., Gao, J., Kurtyka, C., Chen, H., Yu, C., Wu, D., Mittal, A., Beg, A. A., Chellappan, S. P., et al. (2013) · Oncogene · doi:10.1038/onc.2012.39 · Cited by 73 · cited 1×
“Best response to nivolumab, n (%) Complete response 1 (5) Partial response 1 (4) Stable disease 9 (43) Disease progression 8 (38) Not evaluable 2 (10)”
BackgroundRetractedPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 1×
“*Large cell carcinoma (1), adenosquamous (1).”
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Self-citationPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335 · cited 1×
“Best response to nivolumab, n (%) Complete response 1 (5) Partial response 1 (4) Stable disease 9 (43) Disease progression 8 (38) Not evaluable 2 (10)”
BackgroundMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Cited by
Bagchi, S., Yuan, R., & Engleman, E. G. (2021) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-042020-042741 · Cited by 2,189
Roles of IFN-γ in tumor progression and regression: A review
Jorgovanovic, D., Song, M., Wang, L., & Zhang, Y. (2020) · Biomarker Research · doi:10.1186/s40364-020-00228-x · Cited by 1,234
“Similarly, a four-gene IFN-γ signature (IFNG, CD274, LAG3, and CXCL9) has been suggested as identifying pattern for urothelial and NSCLC patients who can benefit from the anti-PD-L1 antibody durvalumab [104, 105].”
BackgroundInterferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion
Castro, F., Cardoso, A. P., Gonçalves, R. M., Serre, K., & Oliveira, M. J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00847 · Cited by 1,224
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
Yi, M., Jiao, D., Xu, H., Liu, Q., Zhao, W., Han, X., & Wu, K. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0864-3 · Cited by 764
“IFNG mRNA expression extracted from formalin-fixed paraffin-embedded tissue specimens is positively related with the effect of anti-PD-1/PD-L1 treatment [55].”
BackgroundLu, S., Stein, J. E., Rimm, D. L., Wang, D. W., Bell, J. M., Johnson, D. B., Sosman, J. A., Schalper, K. A., Anders, R. A., Wang, H., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1549 · Cited by 607
Metadata
- Authors
- Karachaliou, N., Gonzalez-Cao, M., Crespo, G., Drozdowskyj, A., Aldeguer, E., Gimenez-Capitan, A., Teixido, C., Molina-Vila, M. A., Viteri, S., De Los Llanos Gil, M., Algarra, S. M., Perez-Ruiz, E., Marquez-Rodas, I., Rodriguez-Abreu, D., Blanco, R., Puertolas, T., Royo, M. A., & Rosell, R.
- Affiliations
- Instituto Oncológico Dr. Rosell (ES)
- Instituto Oncológico Dr Rosell (IOR), Quirón-Dexeus University Institute, Barcelona, Spain
- Hospital Universitario de Burgos (ES)
- Pivotal (Spain) (ES)
- Pangaea Oncology, Laboratory of Molecular Biology, Quirón-Dexeus University Institute, Barcelona, Spain
- Clínica Universitaria de Navarra, Pamplona, Spain
- Hospital Costa del Sol, Oncology Department, REDISSEC, Marbella, Spain
- Hospital General Universitario Gregorio Marañón, Madrid, Spain
- Hospital Universitario Insular De Gran Canaria, Las Palmas De Gran Canaria, Spain
- Consorci Sanitari de Terrassa (ES)
- Hospital Universitario Miguel Servet, Zaragoza, Spain
- Hospital Universitario Doctor Peset (ES)
- Corresponding author
- Karachaliou, Niki
- Venue
- Therapeutic Advances in Medical Oncology
- Publisher
- SAGE Publications
- Published
- 2018-01-01
- Volume
- 10
- Pages
- 1758834017749748-1758834017749748
- ISSN
- 1758-8340 (ISSN-L)
- 1758-8359
- PMC
- PMC5784541
- OpenAlex
- W2794163856
- Cited by
- 285
- References
- 76
- Citations by year
- 2026: 20 · 2025: 27 · 2024: 18 · 2023: 41 · 2022: 42 · 2021: 48 · 2020: 41 · 2019: 26 · 2018: 21
- FWCI
- 12.87
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Therapeutic Advances in Medical Oncology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Deposito Adademico Digital Universidad De Navarra (University of Navarra) (submittedVersion, cc-by-nc)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- “la Caixa” Foundation
- Fundación Bancaria Caixa d'Estalvis i Pensions de Barcelona
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- interferon-gamma, immune checkpoint blockade, non-small cell lung cancer, melanoma, PD-L1, nivolumab, pembrolizumab, predictive biomarkers, STAT3, IKBKE, STAT1, CD8+ T cell infiltration, progression-free survival, overall survival
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients. https://app.cochat.ai/papers/10.1177/1758834017749748
- The paper
- Karachaliou, N., Gonzalez-Cao, M., Crespo, G., Drozdowskyj, A., Aldeguer, E., Gimenez-Capitan, A., Teixido, C., Molina-Vila, M. A., Viteri, S., De Los Llanos Gil, M., Algarra, S. M., Perez-Ruiz, E., Marquez-Rodas, I., Rodriguez-Abreu, D., Blanco, R., Puertolas, T., Royo, M. A., & Rosell, R. (2018). Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients. Therapeutic Advances in Medical Oncology. https://doi.org/10.1177/1758834017749748
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.